Mantia-Smaldone, GM and Edwards, RP and Vlad, AM
(2011)
Targeted treatment of recurrent platinum-resistant ovarian cancer: Current and emerging therapies.
Cancer Management and Research, 3 (1).
25 - 38.
Abstract
With advances in surgical techniques and chemotherapeutic agents, mortality rates from epithelial ovarian cancer (EOC) have slightly decreased over the last 30 years. However, EOC still ranks as the most deadly gynecologic cancer with an overall 5-year survival rate of 45%. Prognosis is especially disappointing for women with platinum-resistant disease, where 80% of patients will fail to respond to available therapies. Emerging treatment strategies have subsequently focused on targets which are integral to tumor growth and metastasis. In this review, we will focus on those innovative agents currently under investigation in clinical trials. © 2011 Mantia-Smaldone et al, publisher and licensee Dove Medical Press Ltd.
Share
Citation/Export: |
|
Social Networking: |
|
Details
Item Type: |
Article
|
Status: |
Published |
Creators/Authors: |
|
Date: |
31 January 2011 |
Date Type: |
Publication |
Journal or Publication Title: |
Cancer Management and Research |
Volume: |
3 |
Number: |
1 |
Page Range: |
25 - 38 |
Refereed: |
Yes |
Article Type: |
Review |
Date Deposited: |
12 Dec 2012 20:49 |
Last Modified: |
23 Jan 2019 05:55 |
URI: |
http://d-scholarship.pitt.edu/id/eprint/16858 |
Metrics
Monthly Views for the past 3 years
Plum Analytics
Actions (login required)
|
View Item |